What is the appropriate method to switch a patient from nightly Humulin N (NPH insulin) 76 U to once‑daily insulin degludec (Tresiba)?

Switching from Humulin N 76 Units to Tresiba

Start Tresiba at 61 units once daily (80% of the current NPH dose) and monitor blood glucose closely for the first several days after the switch.

Dosing Conversion Algorithm

Based on the FDA-approved prescribing information for Tresiba and current ADA guidelines, the conversion follows this specific approach:

For Adults:

• Calculate starting dose: 76 units × 80% = 61 units of Tresiba once daily 1
• The FDA label explicitly states for adults switching from intermediate-acting insulin (like NPH) to start Tresiba "at the same unit dose as the total daily long or intermediate-acting insulin unit dose" 1
• However, the 2025 ADA Standards of Care recommend using 80% of the current bedtime NPH dose when converting to a basal analog to minimize hypoglycemia risk 2

Critical Implementation Details:

Timing considerations:

• Adults can inject Tresiba at any time of day (provides flexibility NPH doesn't offer) 1
• Ensure at least 8 hours between consecutive Tresiba injections if dose timing varies 1

Monitoring intensity:

• Increase frequency of blood glucose monitoring during the transition period 1
• The first 3-7 days are critical due to Tresiba's ultra-long half-life (>42 hours) and different pharmacokinetic profile 3

Why This Dose Reduction Matters

The 20% dose reduction is clinically important because:

1. Tresiba has a flatter, more stable glucose-lowering profile than NPH with less peak effect 3
2. Lower risk of nocturnal hypoglycemia compared to NPH, meaning the same unit dose may have greater effective glucose-lowering 3
3. Ultra-long duration of action (>42 hours) means insulin stacking is a real concern if you start too high 4, 3

Titration After Switch

After initiating at 61 units:

• Wait 3-4 days between dose adjustments to allow steady-state to be reached 2
• Titrate by 2 units every 3 days based on fasting plasma glucose to reach individualized FPG goal 2
• Target FPG is typically 80-130 mg/dL, but should be individualized 5
• If hypoglycemia occurs without clear cause, reduce dose by 10-20% 2

Common Pitfalls to Avoid

Do NOT convert unit-for-unit (76 units to 76 units) in this scenario. While the FDA label states adults can switch at the same dose, the conservative approach of 80% dosing is safer given:

• The relatively high dose (76 units suggests significant insulin resistance OR this may be a pediatric patient)
• NPH's shorter duration means patients may have breakthrough hyperglycemia that Tresiba's longer action will cover more effectively
• Risk of severe hypoglycemia outweighs risk of temporary hyperglycemia during titration

Special consideration: If this is a pediatric patient (age 1 year or older), the 80% dose reduction is mandatory per FDA labeling 1, making the starting dose 61 units even more clearly appropriate.

Formulation selection: With a 61-unit dose, either Tresiba U-100 or U-200 FlexTouch pen is appropriate. The U-200 pen delivers doses in 2-unit increments up to 160 units per injection, which would work well here 1.